3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Lung Neoplasms
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
High-risk Leukemias
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Bronchogenic
1
Interventions
Gemcitabine
17
pembrolizumab
16
Cisplatin
14
enfortumab vedotin
7
avelumab
7
Nivolumab
6
Docetaxel
6
atezolizumab
5
Paclitaxel
5
Cystectomy
5
sacituzumab govitecan
4
durvalumab
4
Mitomycin
4
Cystoscopy
4
Carboplatin
4
vofatamab
3
tremelimumab
3
Radiotherapy
3
Magnetic Resonance Spectroscopy
3
vinflunine
2
tisotumab vedotin
2
poly ICLC
2
cemiplimab
2
aldesleukin
2
Transurethral Resection of Bladder
2
Radiotherapy, Intensity-Modulated
2
Ipilimumab
2
Interleukin-2
2
Immunoglobulin G
2
Clinical Trials, Phase II as Topic
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Urinary Bladder Neoplasms
×
Interleukin-15
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled